Analysis of the prevalence of the medicinal syndrome of icenco-cushing among patients with rheumatological profile
Relevance: Glucocorticoids, being both drugs and natural hormones of the adrenal cortex, have not only the necessary pharmacological effect, but also contribute to the development of changes in the endocrine system of the body. As a result of such transformations, exogenous Itsenko-Cushing's syndrome may develop. Therefore, the task of modern medicine is the timely prediction and correction of this condition. Objective: To analyze the prevalence of Itsenko-Cushing's drug syndrome among patients of the rheumatology department, depending on the nosological form, duration and scheme of taking synthetic glucocorticoids. Methods: Hypothetical-deductive method, comparison, probability-statistical methods, generalization. Results: In total, the rheumatology department received treatment: in 2017 - 1468 people, in 2018 - 1433 people, in 2019 - 1389 people. Including nosologies in which glucocorticoids are used for a long time: with a diagnosis of systemic lupus erythematosus - 57, 48 and 65 people, respectively, rheumatoid arthritis - 365, 320 and 334 people, respectively, systemic vasculitis - 24, 35 and 24 people, respectively, systemic scleroderma - 61, 48 and 56 people, respectively. Itsenko-Cushing's drug syndrome was determined in 56.4% of patients receiving glucocorticoid therapy for systemic lupus erythematosus, in 34.2% with rheumatoid arthritis, in 58.1% of patients undergoing treatment for systemic vasculitis and in 57.4% with systemic scleroderma. Conclusion: One of the important problems of modern medicine is the Itsenko-Cushing drug syndrome. The use of glucocorticosteroids for a long time or in high doses leads to the development of serious complications. This phenomenon requires comprehensive accounting, analysis and prediction of the likelihood of adverse consequences and, as a consequence, the appointment of modern therapy in order to prevent and promptly correct possible complications.